Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

569
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
569
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

779
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
779
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

771
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
771
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

422
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
422
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.5K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy-induced Cushing syndrome: diagnosis and management of a rare endocrine disorder.

JCEM case reports·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Delayed Diagnosis of McCune-Albright Syndrome in Adulthood Revealed by Spinal Fibrous Dysplasia: Report of 2 Cases.

JCEM case reports·2025
Same author

Patients with langerhans cell histiocytosis and hypothalamic-pituitary involvement: insights from the HEROS study cohort.

Pituitary·2025
Same author

Adrenal function, morbidity and mortality in patients with COVID-19.

Endocrine·2025
Same author

Consensus on acromegaly therapeutic outcomes: an update.

Nature reviews. Endocrinology·2025

Related Experiment Video

Updated: Oct 27, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.1K

Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.

Yona Greenman1, Marcello D Bronstein2

  • 1Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel.

European Journal of Endocrinology
|July 21, 2021
PubMed
Summary

Cabergoline may offer a medical treatment option for progressing non-functioning pituitary adenomas (NFPA). This debate reviews evidence for and against its use in managing residual tumor growth after surgery.

More Related Videos

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

585
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

3.8K

Related Experiment Videos

Last Updated: Oct 27, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.1K
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

585
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

3.8K

Area of Science:

  • Neuroendocrinology
  • Oncology
  • Pituitary Medicine

Background:

  • Non-functioning pituitary adenomas (NFPA) often require surgery but commonly leave residual tumor.
  • Current follow-up involves surveillance, with up to 50% experiencing growth, necessitating further treatments like surgery or radiation.
  • NFPA are the sole pituitary tumor type lacking an approved medical therapy.

Purpose of the Study:

  • To debate the evidence for and against using cabergoline in treating non-functioning pituitary adenomas with residual tumor growth.
  • To explore potential medical management for a condition currently lacking approved pharmacological options.

Main Methods:

  • Review of existing clinical evidence and research findings regarding cabergoline's efficacy and safety in NFPA.
  • Discussion of arguments supporting and opposing cabergoline as a treatment for progressing NFPA.

Main Results:

  • Evidence suggests cabergoline may be effective in controlling residual NFPA growth.
  • Concerns exist regarding long-term efficacy, side effects, and optimal dosing for NFPA management.
  • The debate highlights the need for further research and clinical trials.

Conclusions:

  • Cabergoline presents a potential medical treatment avenue for progressing NFPA, addressing a significant unmet need.
  • Further investigation is crucial to establish its role, safety, and efficacy in clinical practice.
  • The use of cabergoline for NFPA requires careful consideration of the available evidence and patient-specific factors.